Clinical trials of HIV-infected individuals using ZFN-modified autologous T cells and HSPCs
| Clinical trial . | Status . | Cohorts/study populations . | Cell type . | ZFN delivery method . | Conditioning regimen . |
|---|---|---|---|---|---|
| NCT00842634 phase 1 | 2009-2013 Completed41 | On ART, aviremic, CD4 counts >450 | CD4 T cells | Adenovirus | None |
| On ART, aviremic, CD4 counts 200-500, ATI | |||||
| NCT01044654 phase 1 | 2009-2014 Completed | On ART, aviremic, CD4 counts 200-500 | CD4 T cells | Adenovirus | None |
| On ART, aviremic, CD4 counts >500, and CCR5Δ32 heterozygotes, ATI | |||||
| NCT01252641 phase 1/2 | 2010-2015 Completed | Not on ART, CD4 counts >500 | CD4 T cells | Adenovirus | None |
| NCT01543152 phase 1 | 2011-2016 Recruiting | On ART, aviremic, CD4 counts >500, ATI | CD4 T cells, and CD4/CD8 T cells | Adenovirus | Cytoxan (dose escalation) |
| NCT02225665 phase 1/2 | 2014-2018 Active, not recruiting | On ART, aviremic, CD4 counts >500, ATI | CD4/CD8 T cells | mRNA | Cytoxan (1 g/m2) |
| NCT02388594 phase 1 | 2015-2017 Recruiting | On ART, aviremic, CD4 counts >450, ATI | CD4 T cells | mRNA | Cytoxan (1 g/m2) |
| NCT02500849 phase 1 | 2015-2018 Recruiting | On ART, aviremic, CD4 counts 200-500, ATI | CD34 HSPC | mRNA | Busulfan (dose escalation) |
| Clinical trial . | Status . | Cohorts/study populations . | Cell type . | ZFN delivery method . | Conditioning regimen . |
|---|---|---|---|---|---|
| NCT00842634 phase 1 | 2009-2013 Completed41 | On ART, aviremic, CD4 counts >450 | CD4 T cells | Adenovirus | None |
| On ART, aviremic, CD4 counts 200-500, ATI | |||||
| NCT01044654 phase 1 | 2009-2014 Completed | On ART, aviremic, CD4 counts 200-500 | CD4 T cells | Adenovirus | None |
| On ART, aviremic, CD4 counts >500, and CCR5Δ32 heterozygotes, ATI | |||||
| NCT01252641 phase 1/2 | 2010-2015 Completed | Not on ART, CD4 counts >500 | CD4 T cells | Adenovirus | None |
| NCT01543152 phase 1 | 2011-2016 Recruiting | On ART, aviremic, CD4 counts >500, ATI | CD4 T cells, and CD4/CD8 T cells | Adenovirus | Cytoxan (dose escalation) |
| NCT02225665 phase 1/2 | 2014-2018 Active, not recruiting | On ART, aviremic, CD4 counts >500, ATI | CD4/CD8 T cells | mRNA | Cytoxan (1 g/m2) |
| NCT02388594 phase 1 | 2015-2017 Recruiting | On ART, aviremic, CD4 counts >450, ATI | CD4 T cells | mRNA | Cytoxan (1 g/m2) |
| NCT02500849 phase 1 | 2015-2018 Recruiting | On ART, aviremic, CD4 counts 200-500, ATI | CD34 HSPC | mRNA | Busulfan (dose escalation) |
Information obtained from website Clinicaltrials.gov and publically reported by sponsors.